Nexalin Technology, INC Form 4 insider transactions

Nexalin Technology CEO Mark White was granted 1,000,000 stock options with an exercise price of $0.83, exercisable immediately.

Nexalin Technology's CFO, Justin Van Fleet, was granted 100,000 stock options at an exercise price of $0.83, exercisable immediately.

Nexalin Technology's Chief Medical Officer, David Owens, was granted 1,000,000 stock options at an exercise price of $0.83, effective December 19, 2025.

Nexalin Technology's Sr. VP of Quality and Regulatory, Carolyn Shelton, was granted 100,000 stock options at an exercise price of $0.83, subject to shareholder approval.

Nexalin Technology Director Ben Hu received a grant of 100,000 stock options at an exercise price of $0.83, exercisable from December 19, 2025.

Nexalin Technology Director Alan Kazden was granted 100,000 stock options at an exercise price of $0.83, contingent on future shareholder approval.

Nexalin Technology Director Leonard Osser acquired 83,333 shares of common stock, increasing his beneficial ownership to 1,618,577 shares, with the transaction dated for September 29, 2025.

Nexalin Technology's Chief Medical Officer, David Owens, reported a planned acquisition of 36,459 common shares effective September 29, 2025, under a Rule 10b5-1 plan.

Nexalin Technology Director Ben Hu reported the acquisition of 36,459 shares of common stock, increasing his total beneficial ownership to 377,095 shares.

Nexalin Technology Director Alan Kazden reported the acquisition of 36,459 shares of common stock, increasing his indirect beneficial ownership to 119,590 shares.

Nexalin Technology, Inc. granted Senior VP Carolyn Shelton an option to purchase 20,000 shares of common stock at an exercise price of $2.95.

Nexalin Technology's Chief Medical Officer, David Owens, acquired 303,125 stock options with an exercise price of $0.96, increasing his total beneficial ownership to 1,484,809 derivative securities.

Nexalin Technology directors Marilyn Elson and Leonard Osser reported the disposition of 23,150 common stock warrants just nine days before their expiration.

Marilyn Elson, a Director and 10% Owner, and Leonard Osser, an Officer, of Nexalin Technology, Inc. were granted 300,000 stock options at an exercise price of $1.15 per share, vesting over several years.

Carolyn Hamby Shelton, Sr. VP of Quality and Regulatory at Nexalin Technology, Inc., reported the acquisition of 6,000 shares of common stock on March 12, 2025.

Mark White, President and CEO of Nexalin Technology, Inc., was granted stock options to purchase shares of common stock.

Chief Medical Officer David Owens reports acquisition of stock options in Nexalin Technology, Inc.

David Owens, Chief Medical Officer of Nexalin Technology, Inc., purchased 1,000 shares of common stock at $3.10 per share on February 4, 2025.

David Owens, Chief Medical Officer of Nexalin Technology, Inc., purchased 1,000 shares of common stock at $2.98 per share on February 4, 2025.

David Owens, Chief Medical Officer of Nexalin Technology, recently purchased 1,500 shares of common stock, increasing his total holdings in the company.

Nexalin Technology's Chief Medical Officer, David Owens, has increased his holdings in the company through open market purchases of common stock.

David Owens, Chief Medical Officer of Nexalin Technology, recently purchased 500 shares of common stock at $2.19 per share, increasing his direct holdings to 148,293 shares.

Marilyn Elson and Leonard Osser, both with ties to Nexalin Technology, report changes in their beneficial ownership of common stock, including the acquisition of 700,000 shares at $0.

Director Leslie Bernhard acquired 49,838 shares of Nexalin Technology common stock on September 30, 2024.

Director Ben Hu acquired 175,000 shares of Nexalin Technology, Inc. on September 30, 2024.

Marilyn Elson and Leonard Osser, both directors and 10% owners of Nexalin Technology, report changes in their beneficial ownership of common stock.

Marilyn Elson and Leonard Osser, both connected to Nexalin Technology, report changes in their beneficial ownership, including transactions involving common stock warrants.

David Owens, Chief Medical Officer of Nexalin Technology, recently purchased 1,000 shares of common stock at $0.95 per share.

David Owens, Chief Medical Officer of Nexalin Technology, Inc., purchased 1,000 shares of common stock at $1.75 per share on June 28, 2024.

David Owens, Chief Medical Officer of Nexalin Technology, Inc., purchased 1,619 shares of common stock at $0.71 per share on June 18, 2024.